Identifying safe, effective, and affordable evidence-based dermatologic treatments for older adults can be challenging because of age-related changes in the skin, comorbidities, polypharmacy, mobility issues, and cognitive changes. Phototherapy has been shown to be an effective nonpharmacologic treatment option for multiple challenging dermatologic conditions, however, few studies have specifically examined its effectiveness in older adults. The challenge for older patients with psoriasis and dermatitis is that the conditions can be difficult to control and often require multiple treatment modalities. Patients with psoriasis also have a higher risk for diabetes, dyslipidemia, and cardiovascular disease compared to other older patients, which poses treatment challenges and makes nonpharmacologic treatments even more appealing.

Recent studies show that phototherapy can help decrease the use of dermatologic medications. Foerster and colleagues found that adults with psoriasis who were treated with phototherapy significantly decreased their use of topical steroids (24.5% fewer patients required steroid creams and 31.1% fewer patients required psoriasis-specific topicals) (P<.01) while their use of non-psoriasis-specific medications did not change. Click and colleagues identified a decrease in medication costs, health care utilization, and risk for immunosuppression in patients treated with phototherapy when compared to those treated with biologics and apremilast. Methotrexate is a common dermatologic medication that is highly associated with increased risks in elderly patients because of impaired immune system function and the presence of comorbidities (eg, kidney disease, obesity, diabetes, fatty liver), which increase in prevalence with age. Combining phototherapy with methotrexate can substantially decrease the amount of methotrexate needed to achieve disease control, thereby decreasing the methotrexate-associated risks. Findings from these studies suggest

PRACTICE POINTS
• With appropriate nursing care, phototherapy can be safe and effective for a variety of conditions in elderly patients.
• Compared to younger patients, elderly patients may need more sessions to achieve comparable clearance rates.
• The increased prevalence of photosensitizing medications in the elderly population will require careful adjustments in dosing.

From the University of Washington, Seattle. Drs. Matthews and Pike are from the School of Nursing. Dr. Chien is from the School of Medicine. Drs. Matthews and Chien also are from Kaiser Permanente Dermatology, Bellevue, Washington.

The authors report no conflict of interest.

Correspondence: Sarah W. Matthews, DNP, University of Washington, 1959 NE Pacific St, Box 357263, Seattle, WA 98195-7263 (sarahm09@uw.edu).

doi:10.12788/cutis.0307
that a safe, effective, cost-effective, and well-tolerated nonpharmacologic alternative, such as phototherapy, is highly desirable and should be optimized. Unfortunately, most studies that report the effectiveness of phototherapy are in younger populations.

This retrospective study aimed to (1) identify the most common dermatologic conditions treated with phototherapy in older adults, (2) examine the effectiveness and safety of phototherapy in older adults, and (3) compare the outcomes with 2 similar studies in the United Kingdom16 and Turkey.17

Methods

Design, Setting, Sample, and Statistical Analysis—The institutional review boards of Kaiser Permanente Washington Health Research Institute, Seattle, and the University of Washington, Seattle, approved this study. It was conducted in a large US multispecialty health care system (Group Health, Seattle, Washington [now Kaiser Permanente Washington]) serving approximately 600,000 patients, using billing records to identify all patients treated with phototherapy between January 1, 2015, and December 31, 2015, all who received narrowband UVB (NB-UVB) phototherapy. All adults 65 years and older who received phototherapy treatment during the 12-month study period were included. Patients were included regardless of comorbidities and other dermatologic treatments to maintain as much uniformity as possible between the present study and 2 prior studies examining phototherapy in older adult populations in the United Kingdom16 and Turkey.17 Demographic and clinical factors were presented using frequencies (percentages) or means and medians as appropriate. Comparisons of dermatologic conditions and clearance levels used a Fisher exact test. The number of phototherapy treatments to clearance and total number of treatments were compared between groups of patients using independent sample t-tests.

Phototherapy Protocol—All patients received treatments administered by specially trained phototherapy nurses using a Daavlin UV Series (The Daavlin Company) or an Ultralite unit (Ultralite Enterprises, Inc), both with 48 lamps. All phototherapy nurses had been previously trained to provide treatments based on standardized protocols (Table 1) and to determine the patient’s level of disease clearance using a high to low clearance scale (Table 2). Daavlin’s treatment protocols were built into the software that accompanied the units and were developed based on the American Academy of Dermatology guidelines. The starting dose for an individual patient was determined based on the estimated minimal erythema dose for each phototype. If the patient was using photosensitizing medications, then the protocol guided the nurse to start the patient at a lower dose appropriate for their phototype. Patients with vitiligo were treated with the same starting and escalation doses as patients with Fitzpatrick phototype I because of the assumption that their vitiliginous skin had an increased risk for photosensitivity. A more recent review of the evidence has indicated that this assumption was overly conservative,18 and Kaiser Permanente Washington’s vitiligo protocol has been adjusted.

Results

Patients—Billing records identified 229 total patients who received phototherapy in 2015, of whom 52 (22.7%) were at least 65 years old. The median age was 70 years (range, 65–91 years). Twenty-nine (56%) were men and 35 (67%) had previously received phototherapy treatments. Dermatologic Conditions Treated With Phototherapy—Our primary aim was to identify the most common dermatologic conditions treated with phototherapy in older adults. Psoriasis and dermatitis were the most common conditions treated in the sample (50% [26/52] and 21% [11/52], respectively), with mycosis fungoides being the third most common (10% [5/52]) and vitiligo tied with prurigo nodularis as fourth most common (6% [3/52]) (Figure 1).

Effectiveness and Safety of Phototherapy—Our secondary aim was to examine the effectiveness and safety of phototherapy in older adults. Phototherapy was effective in this population, with 50 of 52 patients (96%) achieving a high or medium level of clearance. The degree of clearance for each of the dermatologic conditions is shown in Figure 2. Psoriasis and dermatitis achieved high clearance rates in 81% (21/26) and 82% (9/11) of patients, respectively. Overall, conditions did not have significant differences in clearance rates (Fisher exact test, П = .10). On average, it took patients 33 treatments to achieve medium or high rates of clearance. Psoriasis cleared more quickly, with an average of 30.4 treatments vs 36.1 treatments for other conditions, but the difference was not significant (t test, П = .26). Patients received an average of 98 total phototherapy treatments; the median number of treatments was 81 due to many being on maintenance therapy over several months. There was no relationship between a history of treatment with phototherapy and the total number of treatments needed to achieve clearance (t test, П = .40), but interestingly, those who had a history of phototherapy took approximately 5 more treatments to achieve clearance. The present study found that a slightly larger number of men were being treated for psoriasis (15 men vs 11 women), but there was no significant difference in response rate based on gender.

Side effects from phototherapy were minimal; 24 patients (46%) experienced grade 1 (mild) erythema at some point during their treatment course. Thirteen (25%) patients experienced grade 2 erythema, but this was a rare event for most patients. Only 1 (2%) patient experienced grade 3 erythema 1 time. Three patients experienced increased itching (6%). Thirteen (25%) patients had no side effects. None developed severe erythema or blisters, and none discontinued phototherapy because of side effects. Over the course of the study year, we found a high degree of acceptance of phototherapy treatments by...
TABLE 1. Phototherapy Treatment Protocols

<table>
<thead>
<tr>
<th>Protocol name</th>
<th>Specific steps</th>
<th>Additional details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starting dose</td>
<td>Fitzpatrick skin phototype determined by referring provider, then the phototherapy nurse uses a table that lists estimated MEDs for each skin type and the starting dose, which is 70% of the MED</td>
<td>Phototype I–VI,* MED not routinely performed</td>
</tr>
<tr>
<td>Dose escalation</td>
<td>Subsequent doses were based on the phototype-driven protocols</td>
<td>Dose increases of 10%–15% of the prior dose based on the nurse’s clinical assessment of the patient at each visit</td>
</tr>
<tr>
<td>Dose adjustments based on outcomes</td>
<td>Dose adjustments were based on 4 variables: (1) time since the last treatment, (2) patient’s response to the prior doses (same, better, worse), (3) photosensitizing medications, (4) erythema and/or itching</td>
<td>Nurse assessed all 4 variables at each visit and adjusted the treatments accordingly</td>
</tr>
<tr>
<td>Treatment frequency</td>
<td>Treatments were administered 3 times weekly during the clearance phase</td>
<td>Tapered to once weekly once condition controlled</td>
</tr>
<tr>
<td>Erythema protocol</td>
<td>If mild erythema occurred but lasted &lt;24 h</td>
<td>Same dose was repeated, then subsequent doses continued at the prior rate of increase</td>
</tr>
<tr>
<td></td>
<td>If moderate erythema occurred and lasted &gt;24 h</td>
<td>Treatments stopped until symptoms resolved; once restarted, the dose was decreased to the prior dose that did not cause erythema, and then increases were resumed at lower increments; if previously 10% increases, changed to 5%; if previously 15% increases, changed to 10%</td>
</tr>
</tbody>
</table>

Abbreviation: MED, minimal erythema dose.

*Phototype I: always burns, never tans (vitiligo included in this category), estimated MED of 175 mJ/cm² (starting dose, 123 mJ/cm²); II: usually burns, sometimes tans but fades quickly, estimated MED of 250 mJ/cm² (starting dose, 175 mJ/cm²); III: sometimes burns, usually tans and persists longer, estimated MED of 325 mJ/cm² (starting dose, 228 mJ/cm²); IV: moderately pigmented, minimally burns, tans easily, estimated MED of 400 mJ/cm² (starting dose, 122.5 mJ/cm²); V: dark brown to black, very darkly pigmented, rarely burns, estimated MED of 475 mJ/cm² (starting dose, 280 mJ/cm²); VI: darker black, extremely rare burns, estimated MED of 550 mJ/cm² (starting dose, 385 mJ/cm²).

TABLE 2. High-Low Clearance Scale

<table>
<thead>
<tr>
<th>Level of clearance</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>High (clear/near)</td>
<td>&gt;90% improvement, or dermatologic disease covering &lt;2% BSA</td>
</tr>
<tr>
<td>Medium</td>
<td>&gt;50% improvement from baseline</td>
</tr>
<tr>
<td>Low</td>
<td>Persistent scaly, thick, red, or itchy lesions in the case of psoriasis, dermatitis, mycosis fungoides, or prurigo nodularis; persistent depigmented macules and patches in the case of vitiligo</td>
</tr>
</tbody>
</table>

Abbreviation: BSA, body surface area.
PHOTOTHERAPY IN OLDER ADULTS

FIGURE 2. Degree of clearance by dermatologic condition.

TABLE 3. Comparison of Conditions Treated

<table>
<thead>
<tr>
<th>Condition treated</th>
<th>Current study (N=52), a n (%)</th>
<th>United Kingdom study b N=37, b n (%)</th>
<th>Turkey study b N=95, b n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psoriasis</td>
<td>26 (50)</td>
<td>19 (51)</td>
<td>37 (39)</td>
</tr>
<tr>
<td>Dermatitis</td>
<td>11 (21)</td>
<td>4 (11)</td>
<td>6 (6)</td>
</tr>
<tr>
<td>MF</td>
<td>5 (10)c</td>
<td>NA</td>
<td>29 (30)</td>
</tr>
<tr>
<td>PN</td>
<td>3 (6)c</td>
<td>4 (11)</td>
<td>NA</td>
</tr>
<tr>
<td>Vitiligo</td>
<td>3 (6)c</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Pruritus</td>
<td>2 (4)c</td>
<td>4 (11)</td>
<td>12 (13)</td>
</tr>
<tr>
<td>Nonspecific rash</td>
<td>2 (4)c</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Grover disease</td>
<td>NA</td>
<td>2 (5)</td>
<td>NA</td>
</tr>
<tr>
<td>Other (scleromyxedema, polymorphic light eruption, granuloma annulare, erythroderma)</td>
<td>NA</td>
<td>4 (11)</td>
<td>NA</td>
</tr>
<tr>
<td>Lichen planus</td>
<td>NA</td>
<td>NA</td>
<td>8 (8)</td>
</tr>
<tr>
<td>Other (morpha, keratoderma, pigmented purpuric dermatosis)</td>
<td>NA</td>
<td>NA</td>
<td>3 (3)</td>
</tr>
</tbody>
</table>

Abbreviations: NB-UVB, narrowband UVB; PUVA, psoralen plus UVA; MF, mycosis fungoides; NA, not available; PN, prurigo nodularis.

aNB-UVB phototherapy only.
bCombination of NB-UVB and PUVA.
cPercentages rounded to nearest whole number.

Copyright Cutis 2021. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher.
older patients: 22 (42%) completed therapy after achieving clearance, 10 (19%) were continuing ongoing treatments (maintenance), and 15 (29%) stopped because of life circumstances (e.g., other health issues, moving out of the area). Only 4 (8%) stopped because of a lack of effectiveness, and 1 (2%) patient because the treatments were burdensome.

Comparison of Outcomes—Our third aim was to compare the outcomes with similar studies in the United Kingdom and Turkey. This study confirmed that phototherapy is being used in older adults (22.7% of this study’s total patients) and is an effective treatment for older patients experiencing a range of challenging inflammatory and proliferative skin diseases similar to studies in the general population. Prior phototherapy studies in elderly patients also found psoriasis to be the most common skin condition treated, with 1 study finding that 51% (19/37) of older phototherapy patients had psoriasis, while another reported 58% (37/95) of older phototherapy patients had psoriasis. These numbers are similar to those in our study, which showed 50% (26/52) of elderly phototherapy patients had psoriasis. Psoriasis is the main indication for treatment with NB-UVB phototherapy in the general population, and because the risk for psoriasis increases with age, it is not surprising that all 3 studies found psoriasis to be the most common indication in elderly phototherapy patients. Table 3 provides further details on conditions treated in all 3 studies.

Comment

Our study found that 94% of patients with psoriasis achieved clearance with an average of 30.4 treatments, which is comparable to the reported 91% response rate with an average of 30 treatments in the United Kingdom. The other similar study in Turkey reported 73.7% of psoriasis patients achieved a 75% or more improvement from baseline with an average of 42 treatments, which may reflect underlying differences in regional skin type. Of note, the scatter chart (Figure 3) shows that several patients in the present study’s analysis are listed as not clear, but many of those patients had low treatment numbers below the mean time to clearance. Thus, the present study’s response rate may have been underestimated.

In the general population, studies show that psoriasis treated with standardized phototherapy protocols typically clears with an average of 20.6 treatments.
The levels of clearance were similar in our study’s older population, but more treatments were required to achieve those results, with an average of 10 more treatments needed (an additional 3.3 weeks). Similar results were found in this sample for dermatitis and mycosis fungoides, indicating comparable clearance rates and levels but a need for more treatments to achieve similar results compared to the general population.

Additionally, in the current study more patients experienced grade 1 (mild) erythema (46%) and grade 2 erythema (25%) at some point in their treatment compared with the United Kingdom (1.89%) and Turkey (35%) studies, though these side effects did not impact the clearance rate. Interestingly, the current study’s scatter chart (Figure 3) illustrates that this side effect did not seem to increase with aging in this population. If anything, the erythema response was more prevalent in the median or younger patients in the sample. Erythema may have been due to the frequent use of photosensitizing medications in older adults in the United States, some of which typically get discontinued in patients 75 years and older (eg, statins). Other potential causes might include the use of phototype vs minimal erythema dose–driven protocols, the standard utilization of protocols originally designed for psoriasis vs other condition-specific protocols, missed treatments leading to increased sensitivity, or possibly shielding mishaps (eg, not wearing a prescribed face shield). Given the number of potential causes and the possibility of overlapping factors, careful analysis is important. With NB-UVB phototherapy, near-erythogenic doses are optimal to achieve effective treatments, but this delicate balance may be more problematic for older adults. Future studies are needed to fully determine the factors at play for this population. In the interim, it is important for phototherapy-trained nurses to consider this risk carefully in the older population. They must follow the prescribed protocols that guide them to query patients about their responses to the prior treatment (eg, erythema, tenderness, itching), photosensitizing medications, missed treatments, and placement of shielding, and then adjust the treatment dosing accordingly.

Limitations—This study had several limitations. Although clinical outcomes were recorded prospectively, the analysis was retrospective, unblinded, and not placebo controlled. It was conducted in a single organization (Group Health [now Kaiser Permanente Washington]) but did analyze data from 4 medical centers in different cities with diverse demographics and a variety of nursing staff providing the treatments. Although the vitiligo treatment protocol likely slowed the response rate for those patients with vitiligo, the numbers were small (ie, only 3 of 52 patients), so the researchers chose to include them in the current study. The sample population was relatively small, but when these data are evaluated alongside the studies in the United Kingdom and Turkey, they show a consistent picture illustrating the effectiveness and safety of phototherapy in the older population. Further epidemiologic studies could be helpful to further describe the usefulness of this modality compared with other treatments for a variety of dermatoses in this age group. Supplementary analysis specifically examining the relationship between the number and type of photosensitizing medications, frequency of erythema, and time to clearance also could be useful.

Conclusion
Older adults with a variety of dermatoses respond well to phototherapy and should have the opportunity to use it, particularly considering the potential for increased complications and costs from other treatment modalities, such as commonly used immunosuppressive pharmaceuticals. However, the current study and the comparison studies indicate that it is important to carefully consider the slower clearance rates and the potential risk for increased erythema in this population and adjust patient education and treatment dosing accordingly.

Unfortunately, many dermatology centers do not offer phototherapy because of infrastructure limitations such as space and specially trained nursing staff. Increasing accessibility of phototherapy for older adults through home treatments may be an alternative, given its effectiveness in the general population. In addition, home phototherapy may be worth pursuing for the older population considering the challenges they may face with transportation to the clinic setting and their increased risk for serious illness if exposed to infections such as COVID-19. The COVID-19 pandemic has brought to light the need for reliable, safe, and effective treatments that can be utilized in the safety of patients’ homes and should therefore be considered as an option for older adults. Issues such as mobility and cognitive decline could pose some complicating factors, but with the help of a well-trained family member or caregiver, home phototherapy could be a viable option that improves accessibility for older patients. Future research opportunities include further examination of the slower but ultimately equivalent response to phototherapy in the older population, the influence of photosensitizing medications on phototherapy effects, and the impact of phototherapy on utilization of immunosuppressive pharmaceuticals in older adults.

REFERENCES